Sinsin Pharmaceutical Co., Ltd.

As of June 30, 2026, Sinsin Pharmaceutical Co., Ltd. carries a market capitalization of 64.93B, placing it among publicly traded companies globally. Its enterprise value stands at 101.66B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Sinsin Pharmaceutical Co., Ltd. has 15.17M shares outstanding.

As of June 30, 2026, Sinsin Pharmaceutical Co., Ltd. trades at a trailing price-to-earnings ratio of 4.82. The price-to-sales ratio is 0.53, and the price-to-book ratio stands at 0.82.

As of June 30, 2026, Sinsin Pharmaceutical Co., Ltd. trades at an EV/EBITDA multiple of 5.46 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 0.83 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 6.99 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. Sinsin Pharmaceutical Co., Ltd. trades at an EV/FCF ratio of 7.79, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 101.66B versus a market cap of 64.93B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Sinsin Pharmaceutical Co., Ltd. maintains a current ratio of 1.07, meaning it holds 1.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 50.90, indicating elevated leverage, while an interest coverage ratio of 13.03 demonstrates strong ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Sinsin Pharmaceutical Co., Ltd. posted a return on equity (ROE) of 18.28, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 11.29 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 9.76, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 12.67, useful for judging operating efficiency across full business cycles. The company generates approximately 337.36M in revenue per employee across its workforce of 364.75, a quick read on workforce productivity versus industry peers. Inventory turnover of 3.65 indicates how many times Sinsin Pharmaceutical Co., Ltd. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Sinsin Pharmaceutical Co., Ltd. recorded 1.28B in income tax expense. That works out to an effective tax rate of 8.73, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 14.69B, leaving 13.47B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 23, 2026, Sinsin Pharmaceutical Co., Ltd.'s stock has declined approximately 23.74% over the past 52 weeks. The 50-day moving average sits at 4,457.60, while the 200-day moving average is 5,059.03.

Over the twelve months ended June 30, 2026, Sinsin Pharmaceutical Co., Ltd. generated 123.05B in revenue and converted that into 13.47B in net income, yielding earnings per share of 883.70. EBITDA reached 18.61B, while operating income came in at 14.54B.

As of June 30, 2026, Sinsin Pharmaceutical Co., Ltd. holds 2.98B in cash and equivalents against 40.08B in total debt, resulting in a net debt position of 36.86B. Total book value stands at 79.10B, with working capital of 4.08B providing operational flexibility.

Sinsin Pharmaceutical Co., Ltd. produced 13.98B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -2.23B in capital expenditures, free cash flow totaled 11.75B - equivalent to 774.88 per share.

Over the twelve months ended June 30, 2026, Sinsin Pharmaceutical Co., Ltd. posted a gross margin of 39.13, reflecting its pricing power and cost economics. The operating margin of 11.81 and net profit margin of 10.94 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, Sinsin Pharmaceutical Co., Ltd. paid dividends of - - per share. The dividend payout ratio of - - indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield stands at 18.10, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 13.36, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Sinsin Pharmaceutical Co., Ltd. shareholders.

As of June 30, 2026, Sinsin Pharmaceutical Co., Ltd. has an Altman Z-Score of 2.50, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.